Učitavanje...
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET on...
Spremljeno u:
| Izdano u: | Oncol Rev |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
PAGEPress Publications, Pavia, Italy
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6065052/ https://ncbi.nlm.nih.gov/pubmed/30093982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/oncol.2018.352 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|